Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BRONKODYL vs AEROLATE SR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Bronkodyl contains theophylline, a xanthine derivative. It acts as a bronchodilator by inhibiting phosphodiesterase, increasing cyclic AMP levels, leading to relaxation of bronchial smooth muscle. Additionally, it blocks adenosine receptors and may have anti-inflammatory effects.
AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.
Treatment of symptoms and reversible airway obstruction associated with chronic asthma,Chronic obstructive pulmonary disease (COPD)
Treatment of symptoms and reversible airway obstruction associated with chronic asthma,Chronic obstructive pulmonary disease (COPD),Apnea of prematurity (off-label)
Theophylline extended-release: 300-600 mg orally every 12 hours; target serum concentration 5-15 mcg/m L.
400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.
Terminal elimination half-life is 3–8 hours in non-smoking adults, 1–5 hours in smokers, and 20–30 hours in premature neonates; clinical context: half-life increases in hepatic impairment, heart failure, and with certain medications (e.g., cimetidine, fluoroquinolones).
Terminal elimination half-life 12 hours (range 10–15 h) in adults; prolonged in hepatic impairment (up to 24 h) and elderly.
Primarily hepatic via cytochrome P450 enzymes, mainly CYP1A2 and CYP3A4. Metabolized to 3-methylxanthine, 1-methyluric acid, and 1,3-dimethyluric acid.
Primarily hepatic via cytochrome P450 enzymes (CYP1A2, CYP2E1, and CYP3A4). Theophylline is metabolized to 1,3-dimethyluric acid, 1-methyluric acid, and 3-methylxanthine.
Renal: approximately 90% as theophylline and its metabolites (1,3-dimethyluric acid, 3-methylxanthine, 1-methyluric acid); biliary/fecal: <10%.
Renal: 60% as unchanged drug; biliary/fecal: 30% as metabolites; 10% as unchanged in feces.
Approximately 40% bound to plasma albumin.
55–65% bound to plasma proteins, primarily albumin.
0.3–0.7 L/kg; clinical meaning: distributes into total body water, with higher Vd in neonates and patients with hepatic cirrhosis.
0.4–0.6 L/kg, indicating distribution into total body water.
Oral (immediate-release): 80–100%; oral (sustained-release): 80–100% (subject to first-pass metabolism); rectal: approximately 80%.
Oral: 90–100% for sustained-release formulation; food decreases rate but not extent (AUC unchanged).
For GFR <30 m L/min: reduce dose by 50% and monitor serum levels; for GFR 30-60 m L/min: reduce dose by 25%.
No dose adjustment required for renal impairment.
Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: reduce dose by 75% or use alternative agent.
Use with caution in severe hepatic impairment (Child-Pugh class C); consider dose reduction by 50%.
Loading dose: 5-7 mg/kg IV over 30 minutes; maintenance: 0.5-1 mg/kg/hour IV continuous infusion or 10-20 mg/kg/day orally divided every 8-12 hours; adjust to achieve serum levels 5-10 mcg/m L.
Children 6-12 years: 200-400 mcg inhaled twice daily. Children over 12 years: same as adult dose.
Start at lower end of dosing range (300 mg/day) and titrate slowly; monitor serum theophylline levels closely due to reduced clearance.
Start at lower end of dosing range (400 mcg twice daily) and titrate to response; monitor for systemic effects.
No FDA black box warning.
No FDA black box warning exists for this drug.
Risk of toxicity due to narrow therapeutic index; monitor serum theophylline levels. Use caution in patients with peptic ulcer, seizure disorders, cardiac arrhythmias, or hepatic impairment. Smoking and certain drugs alter metabolism.
Theophylline has a narrow therapeutic index; serum levels must be monitored to avoid toxicity. Toxicity can include seizures, cardiac arrhythmias, and death. Caution in patients with heart failure, hepatic impairment, or those over 55 years. Risk of toxicity increased by concurrent medications such as cimetidine, fluoroquinolones, and macrolides.
Hypersensitivity to theophylline or any component; pre-existing cardiac arrhythmias (unless on monitoring); uncontrolled seizure disorders; active peptic ulcer disease.
Hypersensitivity to theophylline or any component of the formulation; active seizure disorder; untreated cardiac arrhythmias; severe hypertension; hyperthyroidism; peptic ulcer disease; caution with concurrent use of ephedrine or other sympathomimetics.
High-fat meals may delay absorption; take consistently with food to avoid fluctuations. Charcoal-grilled foods and a high-protein, low-carbohydrate diet can increase metabolism of theophylline, reducing efficacy. Avoid concurrent use with caffeine-containing foods/beverages due to additive CNS stimulation.
High-fat meals may delay absorption. Avoid charcoal-grilled foods and large amounts of caffeine. Grapefruit juice may increase theophylline levels; limit intake.
BRONKODYL (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; animal studies show no consistent teratogenicity. Second and third trimesters: Possible fetal tachycardia and jitteriness with maternal high doses; risk of neonatal withdrawal if used near term.
Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypoglycemia, and reduced uterine contractility; avoid use near term due to potential for neonatal bradycardia and hypoglycemia.
Theophylline is excreted into breast milk with milk-to-plasma ratio approximately 0.60-0.70. Concentrations in milk are about 2/3 of maternal serum levels. Irritability and sleep disturbance reported in nursing infants; monitor infant for signs of caffeine-like effects.
Salbutamol is excreted into breast milk in minimal amounts; estimated infant dose <2% of maternal weight-adjusted dose. No known adverse effects in nursing infants. M/P ratio not established. Use with caution.
Pregnancy may increase elimination of theophylline, especially in the third trimester, requiring dose adjustment. Monitor levels; may need 20-30% higher dose in third trimester. Postpartum, clearance decreases rapidly; reduce dose to prepregnancy levels.
No dose adjustment required for inhaled salbutamol. Increased clearance in late pregnancy may necessitate higher doses for systemic effects; monitor clinical response and adjust accordingly.
BRONKODYL (theophylline) has a narrow therapeutic index; serum levels should be monitored (target 5-15 mcg/m L). Avoid in patients with active peptic ulcer, seizure disorders, or uncontrolled arrhythmias. Cimetidine, ciprofloxacin, and macrolides increase theophylline levels; smoking and rifampin decrease them. Use with caution in heart failure, hepatic impairment, and in elderly patients, as clearance is reduced.
AEROLATE SR contains theophylline; narrow therapeutic index (10-20 mcg/m L). Monitor serum levels, especially with CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine) or inducers (e.g., carbamazepine, phenytoin). SR formulation avoids peak-trough fluctuations; do not crush or chew. Caution in heart failure, hepatic impairment, and elderly.
Take this medication exactly as prescribed; do not double doses if missed.,Avoid consuming large amounts of caffeine (coffee, tea, cola, chocolate) as it may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, tremors, palpitations, or seizures.,Do not change brands or formulations without consulting your doctor, as bioavailability may differ.,Regular blood tests are necessary to monitor theophylline levels.
Take exactly as prescribed; do not crush or chew the sustained-release tablet.,Do not stop suddenly; sudden withdrawal may worsen breathing.,Avoid excessive caffeine (coffee, tea, chocolate) as it may increase side effects.,Report nausea, vomiting, insomnia, palpitations, or seizures immediately.,Keep regular appointments for blood level monitoring.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BRONKODYL vs AEROLATE SR, answered by our medical review team.
BRONKODYL is a Bronchodilator that works by Bronkodyl contains theophylline, a xanthine derivative. It acts as a bronchodilator by inhibiting phosphodiesterase, increasing cyclic AMP levels, leading to relaxation of bronchial smooth muscle. Additionally, it blocks adenosine receptors and may have anti-inflammatory effects.. AEROLATE SR is a Bronchodilator that works by AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BRONKODYL and AEROLATE SR depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BRONKODYL is: Theophylline extended-release: 300-600 mg orally every 12 hours; target serum concentration 5-15 mcg/m L.. The standard adult dose of AEROLATE SR is: 400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BRONKODYL and AEROLATE SR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BRONKODYL is classified as Category C. BRONKODYL (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; animal studies show no consistent teratogenicity. Second and third trimesters: Po. AEROLATE SR is classified as Category C. Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.